- Home
- TRVI vs AXGN Comparison
TRVI vs AXGN Comparison
Compare TRVI & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRVI | AXGN |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRVI | AXGN |
|---|---|---|
| Price | $10.85 | $31.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $20.38 | ★ $33.67 |
| AVG Volume (30 Days) | ★ 1.9M | 782.2K |
| Earning Date | 11-13-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $214,709,000.00 |
| Revenue This Year | N/A | $21.60 |
| Revenue Next Year | N/A | $15.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.72 |
| 52 Week Low | $3.47 | $9.22 |
| 52 Week High | $14.39 | $34.24 |
Technical Indicators
Market Signals| Indicator | TRVI | AXGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 53.88 |
| Support Level | $12.60 | $30.32 |
| Resistance Level | $13.16 | $33.84 |
| Average True Range (ATR) | 0.65 | 1.46 |
| MACD | -0.26 | -0.40 |
| Stochastic Oscillator | 9.28 | 44.34 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About AXGN Axogen Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.